Engineering the Next-Generation Antibody-Oligonucleotide Drug Conjugates & Opportunities for New Disease Indications

4:00 pm - Wednesday 10th March 2027

  • Moving beyond traditional payloads to oligonucleotide conjugates to deliver siRNA-based medicines to patients faster
  • Leveraging the dual capability to open doors to interventions with reduced off-target effects, providing a pathway for highly precise treatments
  • Utilising AOCs for targeted gene silencing: Overcoming the challenge of escaping from cellular compartments and achieving substantial target gene knockdown in solid tumours